[Theoretical and clinical aspects of the use of prostaglandins in glaucoma therapy].
In the first part of the article the main information and recent research on the uveoscleral outflow pathway, including its morphology and physiology were presented. The structure of extracellular matrix of ciliary muscle and the changes of it, that are induced by prostaglandins, resulting in decreasing intraocular pressure were emphasized. In the second part biochemical characteristics of prostaglandin analogues, using nowadays were presented. Their efficacy in reducing intraocular pressure and safety profile were described.
Wierzbowska
Joanna
J
Z Kliniki Okulistycznej Wojskowego Instytutu Medycznego w Warszawie.
Stankiewicz
Andrzej
A
D000577:Amides; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008055:Lipids / Q000627:therapeutic use; D011460:Prostaglandins F / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D000069557:Travoprost; D016896:Treatment Outcome
D000577:Amides; D008055:Lipids; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D011982:Receptors, Prostaglandin; D003008:Cloprostenol; C072630:isopropyl unoprostone; D000077338:Latanoprost; D015237:Dinoprost; D000069580:Bimatoprost; D000069557:Travoprost